Enhertu posts 14.3-month first-line PFS in HER2-mutant NSCLC (DESTINY-Lung04)

Enhertu opens a first-line door in HER2-mutant lung cancer

On 14 September 2026, AstraZeneca reported that Enhertu (trastuzumab deruxtecan) reached a median progression-free survival of 14.3 months as first-line treatment of HER2-mutant advanced non-squamous NSCLC in the Phase III DESTINY-Lung04 trial ^[2]. The topline win — a statistically significant and clinically meaningful PFS improvement over platinum-pemetrexed plus pembrolizumab, the global standard of care in this setting — was first announced on 17 August 2026 ^[1]. AstraZeneca states this is the first Phase III trial to show a first-line PFS benefit for a HER2-directed medicine over the immunotherapy-plus-chemotherapy standard in HER2-mutant NSCLC ^[1].

Why it matters

A genetically defined first-line niche just opened. HER2 mutations occur in roughly 2-4% of NSCLC patients ^[1], and Enhertu is currently approved only for previously treated metastatic HER2-mutant NSCLC and for HER2-positive solid tumours after prior treatment with no satisfactory options ^[1]. DESTINY-Lung04 moves the ADC from a later-line option toward a first-line contender for a molecularly selected population. That challenges the reflex of prescribing immunotherapy plus chemotherapy to every newly diagnosed patient — but where the HER2 mutation is identified at diagnosis, which raises the stakes on upfront sequencing and reflex molecular testing.

What Prognyx could not verify

Overall survival continues to be evaluated as planned ^[1]; its immaturity is flagged by secondary trade coverage rather than a primary AstraZeneca or SEC disclosure ^[3][4]. Prognyx could not locate a ClinicalTrials.gov record confirming the trial's identifier or recruitment status, and AstraZeneca's releases do not state any FDA or EMA filing plan for a first-line HER2-mutant NSCLC indication. Without the hazard ratio and mature OS, the magnitude and durability of the benefit remain open.

Competitive context

DESTINY-Lung04 lands in the same week that GSK reported its Nuvalent-originated ROS1-directed drug Jideytro posted a 94% response rate as first-line treatment for ROS1-positive NSCLC, per data at the World Conference on Lung Cancer ^[8]. That is a separate genetically defined first-line niche, not a direct comparator, but it signals where thoracic oncology is heading: targeted first-line displacement of IO-chemo in narrow, biomarker-selected populations. The Enhertu result also fits AstraZeneca's pattern of pushing the ADC into earlier lines — its combination with pertuzumab was approved in the EU on 1 September 2026 as a first-line regimen for HER2-positive metastatic breast cancer ^[7].

What to watch

• The full DESTINY-Lung04 readout — hazard ratio, confidence interval, p-value and OS maturity — at the next medical meeting AstraZeneca names ^[2].
• Any FDA supplemental filing or EMA submission to convert the PFS win into a first-line label; AstraZeneca's releases state none.

The now-what

For a HER2-focused or thoracic program, three moves are on the table. First, pressure-test your comparator assumptions: if Enhertu wins a first-line label, later-line HER2 NSCLC assets lose their untreated-in-first-line runway and must show benefit post-Enhertu. Second, tie any HER2-mutant NSCLC program to a diagnostics story — first-line positioning is only reachable if the mutation is found at diagnosis. Third, treat the missing hazard ratio and OS as the real catalyst: a modest HR or flat OS at the medical meeting reopens the door that a 14.3-month median appears to close.

Verdict: a credible first-line threat in HER2-mutant NSCLC, but unconfirmed in magnitude — moderate threat, with a window to act that stays open until the full readout and any regulatory filing land.